iDNA Genomics Public (CYS:IDNA) Operating Margin %: 0.00% (As of . 20)


CYS:IDNA iDNA Genomics Public Ltd CYS:IDNA
23 GF Score
Price €22.80
! 2 Warning Signs
View Full Analysis

What is iDNA Genomics Public Operating Margin %?

iDNA Genomics Public CYS:IDNA 23 Operating Margin % is 0.00% as of . 20. GuruFocus rates CYS:IDNA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Operating Margin % is calculated as Operating Income divided by its Revenue. iDNA Genomics Public's Operating Income for the six months ended in . 20 was €0.00 Mil. iDNA Genomics Public's Revenue for the six months ended in . 20 was €0.00 Mil. Therefore, iDNA Genomics Public's Operating Margin % for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for iDNA Genomics Public's Operating Margin % or its related term are showing as below:


CYS:IDNA's Operating Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -3.195
* Ranked among companies with meaningful Operating Margin % only.

iDNA Genomics Public's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

iDNA Genomics Public's Operating Income for the six months ended in . 20 was €0.00 Mil.


iDNA Genomics Public  (CYS:IDNA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


iDNA Genomics Public Operating Margin % Related Terms


iDNA Genomics Public Operating Margin % Historical Data

* Premium members only.

The historical data trend for iDNA Genomics Public's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iDNA Genomics Public Operating Margin % Chart

iDNA Genomics Public Annual Data
Trend
Operating Margin %

iDNA Genomics Public Semi-Annual Data
Operating Margin %

CYS:IDNA vs : Operating Margin % Comparison

For the Diagnostics & Research subindustry, iDNA Genomics Public's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iDNA Genomics Public Operating Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iDNA Genomics Public's Operating Margin % distribution charts can be found below:

* The bar in red indicates where iDNA Genomics Public's Operating Margin % falls into.


CYS:IDNA
23GF Score
iDNA Genomics Public Ltd CYS:IDNA
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iDNA Genomics Public Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

iDNA Genomics Public's Operating Margin % for the fiscal year that ended in . 20 is calculated as

Operating Margin %=Operating Income (A: . 20 ) / Revenue (A: . 20 )
= /
= %

iDNA Genomics Public's Operating Margin % for the quarter that ended in . 20 is calculated as

Operating Margin %=Operating Income (Q: . 20 ) / Revenue (Q: . 20 )
= /
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
iDNA Genomics Public (CYS:IDNA) has a Operating Margin % of 0.00% as of . 20. Operating margin is the ratio of total operating income to net sales. View historical data on iDNA Genomics Public and its competitors.
Is iDNA Genomics Public's Operating Margin % too high?
iDNA Genomics Public's current Operating Margin % is 0.00%. Overall, iDNA Genomics Public has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does iDNA Genomics Public's Operating Margin % compare to ?
iDNA Genomics Public's Operating Margin % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on iDNA Genomics Public and its competitors. iDNA Genomics Public's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iDNA Genomics Public stock overvalued right now?
iDNA Genomics Public (CYS:IDNA) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. iDNA Genomics Public's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For iDNA Genomics Public (CYS:IDNA), the current Operating Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iDNA Genomics Public Business Description

Comparable Companies
Address 7 Hatzidaki Street, Trypiotis, Nicosia, CYP, 1066
iDNA Genomics Public Ltd operates in the field of genomics and biotechnology and specializes in personalized health care. Its purpose is to develop and provide genetic tests in the field of genomics, through professionals (Medical Genomics) and directly to the consumer (Direct-to-Consumer Genomics).
23GF Score

Get the complete analysis for CYS:IDNA

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.80
Price